This week marks a significant moment for the biotechnology sector, particularly for the SPDR S&P Biotech ETF ($XBI). Investors are closely monitoring the ETF as it approaches a critical price point of $100. Current discussions among traders indicate a heightened interest in the ETF, with one trader noting they are still holding their position. Another trader has increased their cash position to 45%, suggesting a cautious approach amid market volatility. The sentiment surrounding $XBI is mixed, with some expressing skepticism about its ability to maintain the $100 level.